Cardarine vs Clenbuterol: what to choose and for whom

The question “Cardarine or Clenbuterol for cutting?” is one of the most common in sports chats. The editorial team considers it not from the standpoint of “which is stronger” but from the standpoint of “what price will have to be paid” — and shows why, for the vast majority of people, the rational answer is to choose neither of these substances.

What people actually want to get

Behind the request “what to choose” there usually stands one of two goals: to shed fat faster before a competition, vacation or photo shoot, or to increase endurance. Clenbuterol is associated with the first goal, Cardarine with both. However, these associations are built mostly on data obtained in animals and on secondhand accounts of other people’s experience.

For clenbuterol there are no quality controlled studies that would show a clinically significant reduction of fat mass in humans compared with diet. For Cardarine, small human studies concerned the lipid profile, not weight loss or athletic performance; the “exercise mimetic” effect was shown in mice.

In other words, the choice between these substances is a choice between two uncertain promises with entirely definite risks. Clenbuterol has documented acute toxicity in humans; Cardarine has carcinogenicity in long-term animal studies, because of which its development was stopped.

If the expected benefit is honestly formulated, it looks modest: a few percent of acceleration of a process that already occurs with a properly organized calorie deficit. If the risk is honestly formulated, it may be irreversible.

Two different types of risk

It is useful to distinguish acute and delayed risk. Clenbuterol is an example of the acute kind: if something goes wrong, a person finds out about it quickly — palpitations, tremor, chest pain, muscle cramps from low potassium. Reports from toxicology centers describe presentations of young people with tachycardia and signs of myocardial injury after taking clenbuterol for weight loss.

Cardarine is an example of delayed risk. A person may feel nothing unusual while taking it, and the question of carcinogenicity that arose in rodent studies has simply never been studied in humans. Such a risk cannot be “felt” or noticed in time.

That is precisely why the notion that Cardarine is “milder” because it does not cause tremor and insomnia is deceptive. The absence of acute symptoms does not equal safety.

Both types of risk are amplified by the unknown composition of the products: preparations from “research” sites do not undergo pharmaceutical control, so the dose, purity and even the active substance itself may differ from what is declared.

For whom these substances are especially dangerous

Some conditions make even a theoretical discussion of the choice unacceptable. Below are the groups for whom the risk is disproportionately high.

For people with eating disorders, both substances pose an additional threat: they reinforce a dangerous drive for rapid weight loss. In that case help from a specialist is appropriate, not a search for a “more effective” agent.

Separately, it is worth mentioning the combination of clenbuterol with caffeine, other stimulants or thyroid hormones — it is precisely such combinations that often figure in severe cases of poisoning. The editorial team deliberately does not discuss any “regimens”, because there is no safe option here.

Finally, women often consider clenbuterol a “women’s” fat burner because of the absence of androgenic effects. However, the cardiovascular risks do not depend on sex.

Warning symptoms: when help is needed

If a person has already taken clenbuterol or an unknown “fat burner”, it is important to know the symptoms that require medical help. Because of clenbuterol’s long half-life they may persist longer than expected.

• A fast pulse at rest, a sensation of interruptions in the heart’s work.
• Pain, pressure or burning in the chest, shortness of breath.
• Pronounced tremor, muscle cramps, weakness (a possible sign of low potassium).
• Severe agitation, feelings of panic, fainting.

For any of these signs one should call emergency services and tell the doctors exactly which substance was taken. Treatment of β2-agonist poisoning is carried out in hospital with ECG and electrolyte monitoring.

For Cardarine acute symptoms are atypical, so the main recommendation is to inform the doctor of the fact of use during scheduled examinations, so that it is taken into account in further monitoring.

And most importantly: do not try to “override” symptoms with other drugs on your own. This only complicates diagnosis.

What works for reducing fat

The most reliable tool is a moderate energy deficit that allows weight to be lost gradually while preserving muscle. The ISSN position statement on diets and body composition (Aragon et al., 2017) emphasizes the importance of high protein content and strength training during the reduction of fat mass.

A common practical guideline is protein at roughly 1.6–2.2 g/kg of body weight per day during a deficit, strength training 2–4 times a week, daily everyday activity and sleep. This approach is slower than advertising promises, but the result lasts longer.

Among supplements with an evidence base for endurance and athletic performance are caffeine in moderate doses (taking individual sensitivity into account), creatine and beta-alanine; they do not “burn fat”, but they help you train better.

If weight does not go down despite following the plan, this is a reason to see a doctor and check thyroid function, glucose levels and other indicators, rather than to look for a stronger agent.

Editorial conclusions

Between Cardarine and clenbuterol there is no safe choice. Clenbuterol is dangerous because of acute cardiovascular complications, Cardarine because of an uncertain long-term risk against a background of data on carcinogenicity in animals. Both substances are banned in sport, and the quality of products on the market is not guaranteed.

For people with heart diseases, anxiety, diabetes, a history of cancer, for athletes and pregnant women, these substances are unacceptable. For everyone else, evidence-based methods of reducing fat deliver results without a risk to life.

We also recommend reading “Cardarine or Clenbuterol: what is the difference”, our overview of evidence-based supplements for endurance and an article on nutrition during cutting.

References

1. Spiller HA, James KJ, Scholzen S, Borys DJ. A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst Abus. 2013;34(3):306–312.
2. Brett J, Dawson AH, Brown JA. Clenbuterol toxicity: a NSW poisons information centre experience. Med J Aust. 2014;200(4):219–221.
3. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405–415.
4. Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol. 2007;27(2):359–365.
5. Aragon AA, Schoenfeld BJ, Wildman R, et al. International Society of Sports Nutrition position stand: diets and body composition. J Int Soc Sports Nutr. 2017;14:16.
6. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; чинна редакція.